Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response

Li, Qian; Che, Feng; Yi, Wei; Jiang, Hanyu; Yun, Zhang; Song, Bin

doi:10.1080/17474124.2021.1974294

Cited by 8 publications

(5 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging methods are still the main means for diagnosis, preoperative assessment and recurrence monitoring of ICC. The liver contrast-enhanced ultrasound, enhanced CT and MRI are commonly used in diagnosis of ICC [17][18][19]. MRI can identify the local and periductal invasion of tumor accurately, display the bile duct system clearly and completely, especially suitable for the evaluation of periductal infiltrative ICC [20].…”

Section: Accurate Diagnosis and Classification Of Iccmentioning

confidence: 99%

The focus clinical research in intrahepatic cholangiocarcinoma

Song

Cai

et al. 2022

Eur J Med Res

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICC), highly invasive and highly heterogeneous, has a poor prognosis. It has been confirmed that many risk factors are associated with ICC including intrahepatic lithiasis, primary sclerosing cholangitis (PSC), congenital abnormalities of the bile ducts, parasite infection, toxic exposures chronic liver disease (viral infection and cirrhosis) and metabolic abnormalities. In recent years, significant progress has been made in the clinical diagnosis and treatment of ICC. Advances in functional and molecular imaging techniques offer the possibility for more accurate preoperative assessment and detection of recurrence. Moreover, the combination of molecular typing and traditional clinical pathological typing provides accurate guarantee for clinical decision-making. Surgical resection is still the only radical treatment for ICC, while R0 resection, lymph node dissection, postoperative adjuvant therapy and recurrence resectomy have been confirmed to be beneficial for patients. New therapies including local therapy, molecular targeted therapy and immunotherapy are developing rapidly, which brings hopeful future for advanced ICC. The combination of traditional therapy and new therapy is the future development direction.

show abstract

Section: Accurate Diagnosis and Classification Of Iccmentioning

confidence: 99%

The focus clinical research in intrahepatic cholangiocarcinoma

Song

Cai

et al. 2022

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…In addition, the guidelines for postoperative surveillance recommend imaging every 3–6 months for 2 years, and then every 6–12 months for up to 5 years ( 9 ). Unfortunately, imaging surveillance has a low medical follow-up and low accuracy in detecting early recurrence ( 23 ). Postoperative monitoring of ESICC patients with high recurrence characteristics based on this criterion may be inadequate.…”

Section: Discussionmentioning

confidence: 99%

Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma

Wang

Huang²,

Shen³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundEarly-stage intrahepatic cholangiocarcinoma (ESICC) with curative resection and lymph node-negative still has the risk of poor prognosis, and there lacks prognosis-assessing tools for these patients. The objective of this study was to develop a prognosis model to predict outcomes and identify risk stratification for ESICC after resection.MethodsTotally 263 patients with ESICC after hepatectomy from January 2012 to January 2022 were analyzed. Clinicopathological factors were selected using multivariable Cox regression analysis and a prognosis model was developed. The performance of the model was evaluated by concordance index (C-index), calibration plots, decision curves analysis (DCA), and net reclassification index (NRI). Kaplan-Meier curves were analyzed for risk stratification of overall survival (OS) and recurrence-free survival (RFS) based on the prognosis model.ResultsThe clinicopathological features that were independently associated with OS of ESICC included carbohydrate antigen19-9, carcinoembryonic antigen, tumor size, tumor differentiation, and T stage. The prognosis model based on these prognostic factors demonstrated excellent discriminatory performance in both derivation cohort (C-index, 0.71) and external validation cohort (C-index, 0.78), which outperformed the TNM staging system (C-index, 0.59) and individual prognostic factors (all C-index < 0.7). Calibration plots, DCA and NRI also showed superior predictive performance. According to the risk for survival, the model stratified patients into low risk (median OS, 66.6 months; median RFS, 24.3 months) and high risk (median OS, 24.0 months; median RFS, 6.4 months) (P < 0.001).ConclusionsOur prognosis model can robustly predict the outcomes of ESICC after curative resection and provide precise evaluation on prognosis risk, facilitating clinicians to develop individualized postoperative treatment options.

show abstract

“…Kim et al reported that risk factors for ICC associated with hepatolithiasis are older age, distal bile duct dilatation in proximal bile duct strictures, liver atrophy, bile duct stones in the left lobe, and postoperative stone recurrence [3] ; in addition, liver uke infection can also cause cholangitis lesions and then lead to malignant transformation of bile duct epithelial cells. In addition, peritumoral vascular encasement and invasion rather than vascular tumor thrombus formation were more common in group B because ICC heterogeneity and invasiveness were higher than HCC, and tumor thrombus formation occurred only in the late stage because the lesion directly encased and invaded peritumoral vessels to narrow and occlude them in the early stage [36,37] .…”

Section: Discussionmentioning

confidence: 99%

The comparative analysis of the clinicopathologic and CT features of hepatitis B virus- positive and negative intrahepatic cholangiocarcinoma patients with different pathological degree differentiation

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background hepatitis B is a risk factor for the development of intrahepatic cholangiocarcinoma. The prognosis of HBV-related ICC remains to be further investigated. AimsTo investigate the clinical, pathological and imaging features of intrahepatic cholangiocarcinoma of hepatitis B virus-positive and -negative patients. MethodsData from January 31, 2012 to December 31, 2019 of 138 patients were retrospectively analyzed. The patients were divided into hepatitis B virus-positive group (group A[n=66]) and virus-negative group (group B[n=72]), and the patients were divided into well-to-moderately differentiated group and poorly differentiated group according to pathological differentiation degree. The differences in clinical, imaging characteristics and the progression-free survival between groups were statistically analyzed. Results There were significant differences in gender, age, HBs antibody, HBc antibody, CA125 and AFP between the two groups (P<0.05); tumor distribution site, maximum diameter, plain scan density, blunting of the inferior hepatic angle, peritumoral bile duct dilatation, vascular encasement invasion, intrahepatic bile duct dilatation and abdominal lymphadenopathy between the two groups (P<0.05); There were statistical differences in tumor plain scan density and signs of vascular encasement and invasion between the two groups with well-to-moderately differentiated tumors (P<0.05); there were statistical differences in tumor plain scan density, signs of vascular encasement and lymphadenopathy between the two groups with poorly differentiated tumors (P<0.05). There was no statistical difference in postoperative PFS between the two groups (P>0.05). Conclusion The clinical and imaging features of ICC of hepatitis B virus-positive and -negative patients are different, and there is little difference in postoperative disease-free survival time.

show abstract

Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response

Cited by 8 publications

References 169 publications

The focus clinical research in intrahepatic cholangiocarcinoma

The focus clinical research in intrahepatic cholangiocarcinoma

Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma

The comparative analysis of the clinicopathologic and CT features of hepatitis B virus- positive and negative intrahepatic cholangiocarcinoma patients with different pathological degree differentiation

Contact Info

Product

Resources

About